Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present argenx SE (NASDAQ: ARGX).

Full DD Report for ARGX

You must become a subscriber to view this report.


Recent News from (NASDAQ: ARGX)

Reader Inquiry: Is InflaRx A Buy On The Dip?
Shares of InflaRx N.V. ( IFRX ) have risen by over 60% year to date and at one point almost tripled from their IPO price point (from last November). After their IPO the stock popped back on my radar after it appeared in a recent edition of my Institutional Top Ideas series as one of the to...
Source: SeekingAlpha
Date: May, 13 2018 02:13
Argenx SE reports Q1 results
Argenx SE (NASDAQ: ARGX ): Q1 operating loss of €14.14M Revenue of €5.57M (-16.4% Y/Y) Press Release More news on: Argenx SE, Earnings news and commentary, Healthcare stocks news,
Source: SeekingAlpha
Date: May, 09 2018 01:10
argenx reports first quarter 2018 financial results and provides business update
May 9, 2018 Breda, the Netherlands / Ghent, Belgium - argenx (Euronext & Nasdaq: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer, today announced financia...
Source: GlobeNewswire
Date: May, 09 2018 01:00
Blog Exposure - Argenx to Present Complete Data from Phase-2 Clinical Trial of Efgartigimod (ARGX-113) at AAN Annual Meeting
Stock Monitor: Amgen Post Earnings Reporting LONDON, UK / ACCESSWIRE / April 26, 2018 / Active-Investors.com has just released a free research report on argenx SE (NASDAQ: ARGX ). If you want access to this report all you need to do is sign up now by clicking the following link www....
Source: ACCESSWIRE IA
Date: April, 26 2018 07:25
Argenx (ARGX) Phase2 Study Of Efgartigimod In Patients With Generalized Myasthenia Gravis - Slideshow
The following slide deck was published by Argenx SE in conjunction with this Read more ...
Source: SeekingAlpha
Date: April, 25 2018 14:17
Institutional Top Ideas Series: Baker Brothers
In the last entry of this series, we took a look at top ideas from Scopia Capital Management (whose performance significantly exceeded that of the IBB during the time frame we looked at). We also took into account the fact that they are a long/short market neutral fund with several outsize...
Source: SeekingAlpha
Date: April, 25 2018 05:17
argenx to present complete data from the Phase 2 proof-of-concept trial of efgartigimod (ARGX-113) in generalized myasthenia gravis at American Academy of Neurology (AAN) Annual Meeting
Eight-week follow-up data show separation of clinical efficacy scores between treatment group and placebo group through the duration of study   Total and pathogenic IgG reduction correlates with disease score improvements          &...
Source: GlobeNewswire
Date: April, 24 2018 01:00
Biotech Forum: The Week Ahead
There are times in life when people must know when not to let go. Balloons are designed to teach small children this ." - Terry Pratchett The big story of the sector last week was the possibility that Shire ( SHPG ) might be targeted as a buyout target by either Takeda (TKPYY) or Aller...
Source: SeekingAlpha
Date: April, 23 2018 13:40
How Do Listed Companies Perform With A U.S. IPO?
US equity markets are an attractive source of capital and liquidity, even for companies that are already listed on foreign exchanges or the OTC markets. Frankfurt-listed MorphoSys (MOR) began trading on Thursday, and four more traded companies are currently scheduled to complete initial ...
Source: SeekingAlpha
Date: April, 19 2018 23:18
Institutional Top Ideas Series: DAFNA Capital Management
In the last entry of this recently rebooted series, we took a look at top ideas from Broadfin Capital (whose performance more than doubled that of the IBB during time frame we looked at). Going forward, I hope to continue delve into the portfolios of successful hedge funds predominantly ...
Source: SeekingAlpha
Date: April, 13 2018 01:03

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-05-1794.2594.4995.7493.9376,679

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-08-134,00516,34424.5044Cover
2018-08-1020,04037,19753.8753Short
2018-08-0920,59142,51748.4300Short
2018-08-085,79515,13138.2989Short
2018-08-077,88512,34863.8565Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on ARGX.


About argenx SE (NASDAQ: ARGX)

Logo for argenx SE (NASDAQ: ARGX)

Not available

 

Contact Information

     

     

    Current Share Structure

       


      Recent Filings from (NASDAQ: ARGX)

      Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
      Filing Type: 6-KFiling Source: edgar
      Filing Date: May, 09 2018
      Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
      Filing Type: 6-KFiling Source: edgar
      Filing Date: April, 24 2018
      Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
      Filing Type: 6-KFiling Source: edgar
      Filing Date: April, 12 2018
      Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
      Filing Type: 6-KFiling Source: edgar
      Filing Date: April, 09 2018
      Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
      Filing Type: 6-KFiling Source: edgar
      Filing Date: March, 26 2018
      Annual and transition report of foreign private issuers under sections 13 or 15(d)
      Filing Type: 20-FFiling Source: edgar
      Filing Date: March, 26 2018
      Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
      Filing Type: 6-KFiling Source: edgar
      Filing Date: March, 22 2018
      Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
      Filing Type: 6-KFiling Source: edgar
      Filing Date: March, 16 2018
      Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
      Filing Type: 6-KFiling Source: edgar
      Filing Date: March, 01 2018
      Prospectus filed under Rule 424(b)(4)
      Filing Type: 424B4Filing Source: edgar
      Filing Date: December, 14 2017

       

       


      Daily Technical Chart for (NASDAQ: ARGX)

      Daily Technical Chart for (NASDAQ: ARGX)


      Stay tuned for daily updates and more on (NASDAQ: ARGX)

      It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

      More to come on (NASDAQ: ARGX)

      Do your DD and if you choose, be ready to go!


       

      The Research: All source information contained in this email is from the public sources mentioned below.

       

       
       

      Thank you

      DD Report
      @DDReports

       

       


      Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in ARGX is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. DD Report does not own any shares of ARGX and does not buy, sell, or trade any shares of ARGX. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: http://dd.report/disclaimer/